Perspective Therapeutics (CATX) Interest Expenses (2010 - 2026)
Perspective Therapeutics (CATX) posted Interest Expenses of $2.8 million for Q1 2026, down 99.91% sequentially from $3.3 billion in Q4 2025, and up 541.31% YoY from $443000.0 in Q1 2025.
Perspective Therapeutics (CATX) Interest Expenses (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Interest Expenses for 17 years, with the latest figure at $2.8 million in Q1 2026.
- Quarterly Interest Expenses rose 541.31% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 541.31% YoY) and the FY2025 annual result came in at $3.3 billion, down 14.5% from the prior year.
- Interest Expenses fell to $2.8 million in Q1 2026 per CATX's latest filing, from $3.3 billion in the prior quarter.
- Over five years, Interest Expenses peaked at $3.8 billion in Q4 2024 and troughed at $7000.0 in Q4 2023.
- A 5-year average of $476.2 million and a median of $2.1 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses slumped 99.97% in 2023, then soared 54551357.14% in 2024.
- Over 5 years, Interest Expenses stood at $20.6 million in 2022, then plunged by 99.97% to $7000.0 in 2023, then jumped by 54551357.14% to $3.8 billion in 2024, then declined by 14.5% to $3.3 billion in 2025, then tumbled by 99.91% to $2.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $2.8 million, $3.3 billion, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 351.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 141.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 176.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 96.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | - |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 114.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -110.42 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 15.80 Mn |
| 10 | Perspective Therapeutics | 396.34 Mn | 396.34 Mn | - | 71,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.57 Mn |
| Jun 30, 2026 | 2.57 Mn |
| Mar 31, 2026 | 2.84 Mn |
| Mar 31, 2026 | 2.84 Mn |
| Dec 31, 2025 | 3.26 Bn |
| Dec 31, 2025 | 3.26 Bn |
| Sep 30, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 443,000.00 |
| Mar 31, 2025 | 443,000.00 |
| Dec 31, 2024 | 3.82 Bn |
| Dec 31, 2024 | 3.82 Bn |
| Sep 30, 2024 | 361,000.00 |
| Sep 30, 2024 | 361,000.00 |
| Jun 30, 2024 | 272,000.00 |
| Jun 30, 2024 | 272,000.00 |
| Mar 31, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.40 Mn |